Symvivo Corporation


Symvivo Corporation

In December 2020, Johnson & Johnson Innovation facilitated an agreement between Janssen Biotech, Inc and Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform.

The preclinical collaboration is focused on opportunities to research, develop and commercialize novel biological therapeutic candidates with the potential to offer patients significant improvements in therapeutic options.

The collaboration has allowed us to branch our platform out into new therapeutic approaches and indications. It has also provided highly meaningful interactions with Johnson & Johnson Innovation’s scientific team, enabling peer-to-peer discussion providing great value and learnings across all our R&D activities.

Alexander Graves
Founder and CEO, Symvivo